ナミキ商事株式会社 医薬品及び創薬化学品の専門商社

医薬品及び創薬化学品の専門商社

検索検索

バイオ製品Bio Products

タンパク質、抗体、アッセイキット

タンパク質カタログ

輸入に関する法規制チェックは、御見積のご依頼をいただいた際に行います。
法規制によっては、定価として記載の価格に追加の費用が発生する場合や供給出来ない場合がございますので、あらかじめご了承ください。

サプライヤー
TargteMol
カタログNo.
TMPY-01337
製品名称
DLL4 Protein, Mouse, Recombinant (His)
タンパク質名
DLL4
Species
Mouse
HOST
HEK293 Cells
100μg: -
お問い合わせ

Overview

Synonyms Dll4, δ4, delta-like 4 (Drosophila), δ-like 4 (Drosophila), Delta4
Characteristics 1. Immobilized DLL4 Protein, Mouse, Recombinant (His Tag) at 2 μg/mL (100 μL/well) can bind NOTCH1 Protein, Mouse, Recombinant (ECD, hFc Tag), the EC50 is 5-30 ng/mL.
2. Measured by the ability of the immobilized protein to enhance BMP2-induced alkaline phosphatase activity in C3H10T1/2 mouse embryonic fibroblast cells. The ED50 for this effect is typically 1-5 ?g/mL in the presence of 500 ng/mL recombinant human BMP2.
Endotoxin Level < 1.0 EU/μg of the protein as determined by the LAL method.
Purity SDS-PAGE: 96.4%; SEC-HPLC: 91.0%
Description DLL4 Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 55.7 kDa and the accession number is Q9JI71.
Reference Martinez JC,et al.(2009) Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues. Histopathology. 54(5): 598-606.,Li JL,et al.(2010) Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity. Future Oncol. 6(7): 1099-103.,Sainson RC,et al.(2007) Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis? Trends Mol Med. 13(9): 389-95.,Yan M,et al.(2007) Delta-like 4/Notch signaling and its therapeutic implications. Clin Cancer Res. 13(24): 7243-6.
URL https://www.targetmol.com/recombinant-protein/dll4_protein_mouse_recombinant_his_tag_

お問い合わせリスト(-)

お問い合わせフォーム